Clinical efficacy and safety of randomized phase 2 trial of pemetrexed-cisplatin or docetaxel-cisplatin plus thoracic intensity-modulated radiation therapy in patients with stage IV lung adenocarcinoma
Li Mei, Geng Yichao, Yang Wengang, Ma Zhu, Li Qingsong, Wang Yu, Luo Daxian, Hu Yinxiang, Ouyang Weiwei, Liu Lingfeng, Su Shengfa, Lu Bing
Department of Thoracic Oncology, Affiliated Hospital of Guizhou Medical University,Guizhou Cancer Hospital, Teaching and Research Section of Oncology, Guizhou Medical University, Guiyang 550004,China
Abstract：Objective To evaluate the clinical efficacy and toxicity of concurrent pemetrexed-cisplatin (PP) or docetaxel-cisplatin (DP) with intensity-modulated radiation therapy (IMRT) in patients with stage ⅠV lung adenocarcinoma. Methods Stage IV lung adenocarcinoma patients with unknown EGFR mutation status or wild-type admitted to Guizhou Cancer Hospital from 2011 to 2016 were randomly assigned into the PP (n=50) and DP groups (n=51).All patients received concurrent IMRT of the chest at a prescription dose of 60-70 Gy. Primary endpoint was 1-year survival rate, and secondary endpoint was acute toxicity. Results The overall response rate was 68.0% and 72.5% in the PP and DP groups (χ2=0.250, P=0.617). The median survival time was 19.6 months (95%CI 13.9-25.3) versus 12.1 months (95%CI 10.7-13.5) in the PP and DP groups. The 1-, 2-and 3-year overall survival rates were 72.0% versus 52.9%, 28.0% versus 17.6%, and 16.0% versus 13. 7%, respectively in the PP and DP groups (P=0.049). In the PP and DP groups, the incidence of grade 3-4 leukopenia was declined by 48% and 63%(P=0.098), and the incidence of grade 3-4 neutropenia was decreased by 34% and 65%(P=0.002), the incidence of grade 3-4 anemia was reduced by 38% and 10%(P=0.024), and the incidence of grade 3-4 thrombocytopenia was declined by 40% and 14%(P=0.003). The incidence rate of grade 2 pneumonitis (P=0.625) and grade 3 esophagitis (P=0.484) were similar in both groups. No patients experienced ≥grade 3 pneumonitis or ≥ grade 4 radiation esophagitis. Conclusions Pemetrexed-cisplatin combined with chemoradiotherapy yields higher clinical efficacy compared with docetaxel-cisplatin plus concurrent chemoradiation in the treatment of stage ⅠV lung adenocarcinoma. The incidence of radiation pneumonitis and esophagitis is similar. The incidence and severity of hematological toxicity does not significantly differ between two groups. Treatment-related toxicity is tolerable in both groups. Clinical Trial Registration Chinese Clinical Trial Registry (ChiCTR-TRC-13004184).
Li Mei,Geng Yichao,Yang Wengang et al. Clinical efficacy and safety of randomized phase 2 trial of pemetrexed-cisplatin or docetaxel-cisplatin plus thoracic intensity-modulated radiation therapy in patients with stage IV lung adenocarcinoma[J]. Chinese Journal of Radiation Oncology, 2018, 27(6): 564-569.
[1] Chirieac LR,Kobzik L.Pathology and molecular pathology of lung cancer[J].Pathol And Epidemiol OfCancer,2017:367-390.DOI:10.1007/978-3-319-35153-7-2. [2] TS Mok,YL Wu,S Thongprasert,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361(10):1018-1020. [3] Schiller JH,Harrington D,Belani CP,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med,2002,346(2):92-98. [4] Scagliotti GV,Parikh P,von Pawel J,et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J]. J Clin Oncol,2008,26(21):3543-3551. [5] 吕家华,李涛,刘丽,等. Ⅳ期寡转移NSCLC同期放化疗后巩固化疗前瞻性Ⅱ期临床研究[J].中华放射肿瘤学杂志,2015,24(6):611-614. Lyu Jh,Li T,Liu L,et al. A prospective phase Ⅱ study of consolidation chemotherapy after concurrent chemoradiotherapy for oligometastatic stage ⅠV non-small cell lung cancer[J].Chin J Radiat Oncol,2015,24(6):611-614. [6] Lopez Guerra JL,Gomez D,Zhuang Y,et al. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis[J]. Int J Radiat Oncol Biol Phys,2012,84(1):e61-e67. [7] 马筑,卢冰,李涛,等. Ⅳ期 NSCLC化疗同期3DRT 的前瞻性多中心Ⅱ期临床研究-PPRA-RTOG 003[J]. 中华放射肿瘤学杂志,2015,24(4):359-363. Ma Z,Lu B,Li T,et al. Aprospective,muticent er,phase Ⅱ clinical study of concurrent chemotherapy and thoracic three-dimensional radiotherapy for stage ⅠV non-small cell lung cancer-(PPRA-RTOG003)[J].Chin J Radiat Oncol,2015,24(4):359-363. [8] Su S,Li T,Lu B,et al. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer:Results of a Multicenter Phase 2 Study From PPRA-RTOG,China[J]. Int J Radiat Oncol Biol Phys,2015,93(4):769-777. [9] Senan S,Brade A,Wang LH,et al. PROCLAIM:Randomized Phase Ⅲ Trial of Pemetrexed-Cisplatin or Etoposide–Cisplat inPlus Thoracic Radiation Therapy Followed by Consolid ation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer[J].J Clin Oncol,2016,34:953-962. [10] 支修益,石远凯,于金明. 中国原发性肺癌诊疗规范(2015年版)[J]. 中华肿瘤杂志,2015,37(1):67-78. Zhi XY,Shi YK,Yu JM,Standard for diagnosis and treatment of primary lung cancer in china,Chin J Oncol[J],2015,37(1):67-78. [11] Parikh RB,Cronin AM,Kozono DE,et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys,2014,89(4):880-887. [12] Koshy M,Malik R,Mahmood U,et al. Comparative effectiveness of aggressive locoregional therapy in metastatic lung cancer:associations between high-dose thoracic radiation therapy and/or chemoradiation therapy and survival in a large population-based cohort[J]. Int J Radiat Oncol Biol Phys,2015,93(3):S68. [13] Choy H,Gerber DE,Bradley JD,et al. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage Ⅲ non-small cell lung cancer:a systematic review of completed and ongoing studies[J]. Lung Cancer,2015,87(3):232-240. [14] Nakamura M,Koizumi T,Hayasaka M,et al. Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage Ⅲ non-small-cell lung cancer[J]. Cancer Chemother Pharmacol,2009,63(6):1091-1096. [15] Yamada K,Shimokawa T,Okamoto H,et al. Randomized phase Ⅱ trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage Ⅲ non-small cell lung cancer (TORG1018):An interim report. 2016,27(suppl6):1190p. [16] Ahn JS,Ahn YC,Kim JH,et al. Multinational randomized phase Ⅲ trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemora diation in inoperable stage Ⅲ non-small-cell lung cancer:KCSG-LU05-04[J].J Clin Oncol,2015,33(24):2660-2666. [17] Park CK,Oh IJ,Kim KS,et al. Randomized phase Ⅲ study of docetaxel plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of nonsquamous non-Small-cell lung cancer:A TRAIL Trial[J]. Clin Lung Cancer,2017,18(4):e289-e296. [18] Wu SG,Yang CH,Yu CJ,et al. Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations[J]. Lung Cancer,2011,72(3):333-339. [19] Socinski MA,Raju RN,Stinchcombe T,et al. Randomized,phase Ⅱ trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage ⅢB/IV non-small cell lung cancer[J]. J Thorac Oncol,2010,5(12):1963-1969. [20] Rodrigues-Pereira J,Kim JH,Magallanes M,et al. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced,nonsquamous non-small cell lung cancer[J]. J Thorac Oncol,2011,6(11):1907-1914. [21] Segawa Y,Kiura K,Takigawa N,et al. Phase Ⅲ trial compa ring docetaxel and cisplatin combination chemotherapy with mitomycin,vindesine,and cisplatin combination chemoth erapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer:OLCSG 0007[J].J Clin Oncol,2010,28(20):3299-3306.
2018, Vol. 27 
